Compound Planning Inc. Boosts Stock Position in Insmed, Inc. $INSM

Compound Planning Inc. increased its holdings in Insmed, Inc. (NASDAQ:INSM) by 2.6% during the 1st quarter, Holdings Channel reports. The firm owned 25,426 shares of the biopharmaceutical company’s stock after buying an additional 652 shares during the period. Compound Planning Inc.’s holdings in Insmed were worth $1,940,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of INSM. M&T Bank Corp lifted its holdings in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company’s stock worth $252,000 after buying an additional 147 shares during the period. Snowden Capital Advisors LLC raised its holdings in shares of Insmed by 2.5% during the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 158 shares in the last quarter. Cullen Frost Bankers Inc. raised its holdings in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 221 shares in the last quarter. Nisa Investment Advisors LLC lifted its stake in Insmed by 6.5% in the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company’s stock worth $287,000 after acquiring an additional 228 shares during the period. Finally, Parkman Healthcare Partners LLC boosted its holdings in Insmed by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company’s stock valued at $2,463,000 after acquiring an additional 235 shares in the last quarter.

Insmed Trading Down 0.5%

Insmed stock opened at $131.88 on Friday. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $133.56. The company has a market cap of $27.88 billion, a P/E ratio of -23.10 and a beta of 0.95. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. The business has a 50-day simple moving average of $107.48 and a two-hundred day simple moving average of $85.66.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analysts’ expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business’s quarterly revenue was up 18.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the firm’s stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total value of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares of the company’s stock, valued at approximately $7,546,758.35. This trade represents a 44.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $127.58, for a total value of $3,189,500.00. Following the transaction, the chief operating officer owned 105,637 shares in the company, valued at $13,477,168.46. This trade represents a 19.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 539,694 shares of company stock worth $53,144,604. Insiders own 3.00% of the company’s stock.

Analysts Set New Price Targets

INSM has been the topic of a number of research reports. William Blair started coverage on shares of Insmed in a report on Wednesday. They set an “outperform” rating on the stock. HC Wainwright boosted their price objective on shares of Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, June 11th. Bank of America raised their target price on shares of Insmed from $94.00 to $109.00 and gave the company a “buy” rating in a research note on Wednesday, June 11th. UBS Group boosted their price target on Insmed from $124.00 to $133.00 and gave the stock a “buy” rating in a research report on Friday, August 8th. Finally, Truist Financial upped their price target on Insmed from $126.00 to $139.00 and gave the stock a “buy” rating in a research note on Thursday, August 14th. Sixteen investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average price target of $132.57.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.